Product Code: GVR-4-68039-728-0
Swine Vaccines Market Growth & Trends:
The global swine vaccines market size is expected to reach USD 2.3 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness a lucrative CAGR of 4.9% from 2022 to 2030. The increasing prevalence and incidence of swine diseases, rising concerns over zoonoses, and strengthening biosecurity measures among swine farms are some of the major factors augmenting the market growth. In addition, the initiatives taken by government and animal healthcare organizations in spreading disease awareness and supporting vaccination drives are further propelling the market growth during the projected period.
The Covid-19 pandemic has directly or indirectly impacted the key player's swine vaccine business operations and resulted in declined financial performance during the initial time. The effect of the pandemic with various production and supply chain bottlenecks delayed the delivery of necessary raw materials or active ingredients and postponed certain research & development activities. However, the simultaneously reported African swine fever outbreaks in several regions pressured the swine vaccine manufacturers with a large demand. In 2020, the OIE reported 9,928 ASF outbreaks in Asia, followed by 4,271 outbreaks in Europe. Hence, considering the situation, the government supported the distribution of swine vaccines with ease of restrictions, which afforded opportunities to rebuild the company's growth.
In addition, the global concern regarding antibiotic resistance is growing in agriculture and veterinary medicine. Thus, several countries have banned the use of antibiotics for livestock farming, including preventive treatment procedures. This act has compelled swine farms to adopt antibiotic-free disease preventive approaches such as vaccination. Furthermore, growing investments by key players to develop advanced products for better diagnosis are likely to propel market growth. For instance, in May 2020, Indian Immunologicals Ltd. introduced the Classical Swine Fever vaccine under the brand name 'Raksha Class', a unique cell culture technology-based vaccine developed in cooperation with the Indian Veterinary Research Institute, Bareilly.
Key players in the market are implementing various strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, among others to maintain a competitive edge in the market. For instance, In March 2022, Ceva launched the sow vaccine, a vaccine containing seven antigens used to treat neonatal diarrhea.
Swine Vaccines Market Report Highlights:
- The PRRS (Porcine Reproductive and Respiratory Syndrome) segment accounted for the largest revenue share in 2021 by type segment owing to its large prevalence in major swine-raising countries. The disease has been considered an epidemic for over 30 years in the U.S. and more than 20 years in China, the leading swine industry
- By product, the inactivated vaccines segment held the largest market share in 2021. These vaccines are more stable than live attenuated vaccines and can provide swine with better immunization. They prevent pathogen replication and therefore do not possess the risk of virulence reversion
- Asia Pacific accounted for the largest market share in 2021 and is expected to grow at the fastest CAGR. Key factors contributing to this notable share include the presence of leading swine production countries such as China coupled with a large meat-consuming population and wide requirement for vaccines to curb current rising disease outbreaks among Asian swine herds
- The market is fairly competitive owing to the presence of major players such as Zoetis, Merck, Ceva, Boehringer Ingelheim International GmbH, Elanco, and Virbac among others. The various strategic initiatives implemented by companies such as acquisitions, collaborations, product launches, and partnerships are greatly contributing to the growth of the market
Table of Contents
Chapter 1 Methodology And Scope
- 1.1 Market Segmentation And Scope
- 1.1.1 Segment Scope
- 1.1.2 Regional Scope
- 1.1.3 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database:
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
- 1.4 Information/Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Bottom - Up Market Estimation
- 1.6.1.2 Top - Down Market Estimation
- 1.6.2 Global Market: Cagr Calculation
- 1.7 List Of Secondary Sources
Chapter 2 Executive Summary
- 2.1 Swine Vaccines Market Outlook
- 2.1.1 Segment Outlook
- 2.1.2 Regional Outlook
- 2.1.3 Competitive Outlook
- 2.2 Swine Vaccines Market Snapshot, 2021
Chapter 3 Swine Vaccines Market Variables, Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Analysis
- 3.1.2 Ancillary Market Analysis
- 3.2 Penetration And Growth Prospect Mapping, By Product Type, 2021
- 3.3 Swine Vaccines Market Dynamics
- 3.3.1 Market Driver Analysis
- 3.3.1.1 Rising Concern About Zoonoses & Strengthening Biosecurity
- 3.3.1.2 Vaccines Act As An Alternative To Antibiotics
- 3.3.1.3 Technological Advancements
- 3.3.1.4 Regulatory Mandates
- 3.3.2 Market Restraint Analysis
- 3.3.2.1 Short Product Exclusivity Period
- 3.3.2.2 Religious And Cultural Restrictions
- 3.3.2.3 Supply Bans On Live Pigs And Pork Products
- 3.4 Industry Analysis
- 3.4.1 Porter's Analysis
- 3.4.1.1 Threat Of New Entrants: Low - Moderate
- 3.4.1.2 Threat Of Substitutes: Moderate To High
- 3.4.1.3 Bargaining Power Of Buyers: Moderate
- 3.4.1.4 Bargaining Power Of Suppliers: Low
- 3.4.1.5 Competitive Rivalry: High
- 3.4.2 Pestel Analysis
- 3.4.2.1 Political & Legal Landscape
- 3.4.2.2 Economic
- 3.4.2.3 Social
- 3.4.2.4 Technological
- 3.4.2.5 Environmental
- 3.5 Regulatory Framework
- 3.5.1 North America
- 3.5.2 Europe
- 3.5.3 Apac
- 3.5.4 Latam
- 3.5.5 Rest Of The World
- 3.6 Product Pipeline Analysis
Chapter 4 Swine Vaccines Market: Covid - 19 Impact Analysis
- 4.1 Covid - 19 Impact Analysis
Chapter 5 Product Estimates & Trend Analysis, 2017 - 2030 (USD Million)
- 5.1 Product Movement Analysis, 2017 - 2030 (USD Million)
- 5.2 Swine Vaccines Market Share Analysis, 2021 & 2030
- 5.2.1 Attenuated Live Vaccines
- 5.2.1.1 Attenuated Live Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 5.2.2 Inactivated Vaccines
- 5.2.2.1 Inactivated Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 5.2.3 Subunit Vaccines
- 5.2.3.1 Subunit Vaccines Market estimates and forecasts, 2017 - 2030 (USD Million)
- 5.2.4 Dna Vaccines
- 5.2.4.1 Dna Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 5.2.5 Recombinant Vaccines
- 5.2.5.1 Recombinant Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 6 Type Estimates & Trend Analysis, 2017 - 2030 (USD Million)
- 6.1 Type Movement Analysis, 2017 - 2030 (USD Million)
- 6.2 Swine Vaccines Market Share Analysis, 2021 & 2030
- 6.2.1 Swine Influenza
- 6.2.1.1 Swine Influenza Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.2 Classical Swine Fever
- 6.2.2.1 Classical Swine Fever Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.3 Porcine Parvovirus
- 6.2.3.1 Porcine Parvovirus Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.4 Porcine Circovirus Type 2
- 6.2.4.1 Porcine Circovirus Type 2 Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.5 M.Hyo
- 6.2.5.1 M.Hyo Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.6 Actinobacillus Pleuropneumonia
- 6.2.6.1 Actinobacillus Pleuropneumonia Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.7 PRRS
- 6.2.7.1 PRRS Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.8 Foot & Mouth Disease
- 6.2.8.1 Foot & Mouth Disease Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.9 Pseudorabies
- 6.2.9.1 Pseudorabies Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.10 Porcine Epidemic Diarrhea
- 6.2.10.1 Pedv Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 6.2.11 Others
- 6.2.11.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 7 Regional Estimates & Trend Analysis, 2017 - 2030 (USD Million)
- 7.1 Regional Market Snapshot
- 7.2 Regional Market Share Analysis, 2021 & 2030
- 7.3 North America
- 7.3.1 North America Swine Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 7.3.2 U.S.
- 7.3.2.1 U.S. Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.3.3 Canada
- 7.3.3.1 Canada Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.4 Europe
- 7.4.1 Europe Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.4.2 France
- 7.4.2.1 France Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.4.3 Germany
- 7.4.3.1 Germany Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.4.4 Spain
- 7.4.4.1 Spain Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.4.5 Italy
- 7.4.5.1 Italy Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.4.6 U.K.
- 7.4.6.1 UK Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.5 Asia Pacific
- 7.5.1 Asia Pacific Swine Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 7.5.2 India
- 7.5.2.1 India Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.5.3 China
- 7.5.3.1 China Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.5.4 Japan
- 7.5.4.1 Japan Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.5.5 Australia
- 7.5.5.1 Australia Swine Vaccines Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 7.5.6 South Korea
- 7.5.6.1 South Korea Swine Vaccines Market Estimates and Forecasts, 2017 - 2030 (USD million)
- 7.6 Latin America
- 7.6.1 Latin America Swine Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 7.6.2 Brazil
- 7.6.2.1 Brazil Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.6.3 Mexico
- 7.6.3.1 Mexico Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.6.4 Argentina
- 7.6.4.1 Argentina Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.7 MEA
- 7.7.1 MEA Swine Vaccines Market Estimates And Forecasts, 2017 - 2030 (USD Million)
- 7.7.2 South Africa
- 7.7.2.1 South Africa Swine Vaccines market estimates and forecasts, 2017 - 2030 (USD Million)
- 7.7.3 Saudi Arabia
- 7.7.3.1 Saudi Arabia Swine Vaccines Market estimates and forecasts 2017 - 2030 (USD Million)
Chapter 8 Competitive Landscape
- 8.1 Market Participation Categorization
- 8.2 Public Companies
- 8.2.1 Company Market Position Analysis
- 8.2.2 Heat Map Analysis
- 8.3 Private Companies
- 8.3.1 List Of Key Companies
Chapter 9 Swine Vaccines Market - Company Profiles
- 9.1 Merck & Co., Inc.
- 9.1.1 Company Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Benchmarking
- 9.1.4 Strategic Initiatives
- 9.2 Ceva
- 9.2.1 Company Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Benchmarking
- 9.2.4 Strategic Initiatives
- 9.3 Zoetis
- 9.3.1 Company Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Benchmarking
- 9.3.4 Strategic Initiatives
- 9.4 Boehringer Ingelheim International GmbH
- 9.4.1 Company Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Benchmarking
- 9.4.4 Strategic Initiatives
- 9.5 Elanco
- 9.5.1 Company Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Benchmarking
- 9.5.4 Strategic Initiatives
- 9.6 Indian Immunologicals Ltd.
- 9.6.1 Company Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Benchmarking
- 9.6.4 Strategic Initiatives
- 9.7 Biogenesis Bago
- 9.7.1 Company Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Benchmarking
- 9.7.4 Strategic Initiatives
- 9.8 Phibro Animal Health Corporation
- 9.8.1 Company Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Benchmarking
- 9.8.4 Strategic Initiatives
- 9.9 KM Biologics (Meiji Holdings Co., Ltd)
- 9.9.1 Company Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Benchmarking
- 9.10 HIPRA
- 9.10.1 Company Overview
- 9.10.2 Product Benchmarking
- 9.10.3 Strategic Initiatives
- 9.11 Virbac
- 9.11.1 Company Overview
- 9.11.2 Financial Performance
- 9.11.3 Product Benchmarking
- 9.11.4 Strategic Initiatives